Broad capabilities, established expertise
As one of the world’s most renowned companies for contract development and manufacturing, we are recognized for our reliable, high-quality service, our global capacity, our innovative technology platforms, and our extensive experience. In 2019 we provided manufacturing services for more than 300 commercial molecules and supported the development of more than 700 pre-clinical and clinical molecules in small and large molecules as well as supporting the launch of pioneering autologous cell therapies.
Success for us is when you, as our partner, are fully satisfied. We continuously improve and innovate to meet your expectations and improve your chances of business success. Our broad capabilities span across biologics, small molecules, bioconjugates, and cell and gene therapies. We manage projects from pre-clinical stage through to commercialization, and our expertise covers both drug substance and drug product.
Cutting it short: Lonza on APIs
Manufacturing timelines for highly potent APIs (HPAPIs) are getting shorter due to faster approvals and improved compounds entering the pipeline. Jakob Bonde and Ryan Littich co-authored a byline to share insights about how pharma companies can establish robust drug substance and drug product procedures to meet these shorted timelines. With the right strategy and CDMO partner, emerging biotech companies can successfully navigate these deadlines while positioning themselves for a successful scale up.
ADC Award Winner
We received the 2021 World ADC Award for Best ADC Contract Manufacturing Provider. It's a testament to our simplified approach in producing complex ADCs and making life-saving treatments accessible for patients.
New Product Introduction Process for cGMP Manufacturing
Introducing our New Product Introduction (NPI) process for Cell & Gene Therapies manufacturing: a standardized, systematic approach to tech transfers, manufacturing and Pre-Approval Inspection readiness to reliably take your therapy to commercialization.
